Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Scheltens

Showing results (821-830 of 903) with videos related to

Pageof 91
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|April 14, 2021
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's diseaseEllen Singleton, Oskar Hansson, Yolande A L Pijnenburg, et al.
Molecular Neurodegeneration|March 29, 2022
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Alzheimer'S Research & Therapy|August 5, 2018
The EMIF-AD PreclinAD study: study design and baseline cohort overviewElles Konijnenberg, Stephen F Carter, Mara Ten Kate, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2021
Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohortSilvia Ingala, Casper De Boer, Larissa A Masselink, et al.
The Lancet. Neurology|October 25, 2020
Amyloid-PET and <sup>18</sup>F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementiasGaël Chételat, Javier Arbizu, Henryk Barthel, et al.
Nature Aging|April 28, 2023
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's diseasePetr Novak, Branislav Kovacech, Stanislav Katina, et al.
The Journal of Prevention of Alzheimer'S Disease|March 18, 2025
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilitiesGiovanni B Frisoni, Federica Ribaldi, Gilles Allali, et al.
The Lancet. Neurology|May 23, 2014
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaBruno Dubois, Howard H Feldman, Claudia Jacova, et al.
Neurology|September 17, 2024
Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without DementiaLuigi Lorenzini, Alessio Maranzano, Silvia Ingala, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 17, 2025
Neurodevelopment and neural environment inform Alzheimer's disease age at onset and phenotypeZachary A Miller, Rik Ossenkoppele, Neill R Graff-Radford, et al.
Pageof 91

Showing results (821-830 of 903) with videos related to

Sort By:
Pageof 91
Journal of Neurology, Neurosurgery, and Psychiatry|April 14, 2021
Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's diseaseEllen Singleton, Oskar Hansson, Yolande A L Pijnenburg, et al.
Molecular Neurodegeneration|March 29, 2022
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's diseasePieter Jelle Visser, Lianne M Reus, Johan Gobom, et al.
Alzheimer'S Research & Therapy|August 5, 2018
The EMIF-AD PreclinAD study: study design and baseline cohort overviewElles Konijnenberg, Stephen F Carter, Mara Ten Kate, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2021
Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohortSilvia Ingala, Casper De Boer, Larissa A Masselink, et al.
The Lancet. Neurology|October 25, 2020
Amyloid-PET and <sup>18</sup>F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementiasGaël Chételat, Javier Arbizu, Henryk Barthel, et al.
Nature Aging|April 28, 2023
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's diseasePetr Novak, Branislav Kovacech, Stanislav Katina, et al.
The Journal of Prevention of Alzheimer'S Disease|March 18, 2025
Brain health services for the secondary prevention of cognitive impairment and dementia: Opportunities, challenges, and the business case for existing and future facilitiesGiovanni B Frisoni, Federica Ribaldi, Gilles Allali, et al.
The Lancet. Neurology|May 23, 2014
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteriaBruno Dubois, Howard H Feldman, Claudia Jacova, et al.
Neurology|September 17, 2024
Association of Vascular Risk Factors and Cerebrovascular Pathology With Alzheimer Disease Pathologic Changes in Individuals Without DementiaLuigi Lorenzini, Alessio Maranzano, Silvia Ingala, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 17, 2025
Neurodevelopment and neural environment inform Alzheimer's disease age at onset and phenotypeZachary A Miller, Rik Ossenkoppele, Neill R Graff-Radford, et al.
Pageof 91